Skip to Content
Merck
  • Progestin-induced heart and neural crest derivatives expressed transcript 2 is associated with fibulin-1 expression in human endometrial stromal cells.

Progestin-induced heart and neural crest derivatives expressed transcript 2 is associated with fibulin-1 expression in human endometrial stromal cells.

Fertility and sterility (2012-10-06)
Hisayuu Cho, Hidetaka Okada, Tomoko Tsuzuki, Akemi Nishigaki, Katsuhiko Yasuda, Hideharu Kanzaki
ABSTRACT

To investigate whether heart and neural crest derivatives expressed transcript 2 (HAND2) regulates fibulin-1 (FBLN1) expression during decidualization of human endometrial stromal cells (ESCs). In vitro experiment. Research laboratory. Twenty-four patients undergoing hysterectomy for benign reasons. ESCs were cultured with various progestins (medroxyprogesterone acetate [MPA], norethisterone, levonorgestrel, dienogest, and P), E(2), dexamethasone, and/or 8-bromoadenosine 3', 5'-cyclic monophosphate (8-Br-cAMP). HAND2 and FBLN1 were silenced by small interfering RNA technology. HAND2 and FBLN1 expression levels were assessed by real-time polymerase chain reaction and Western blot analysis. MPA or E(2) + MPA increased HAND2 mRNA levels in ESCs in a time- and dose-dependent manner, and this stimulatory effect was blocked by RU-486 (P receptor antagonist). HAND2 was increased by E(2) + MPA earlier than FBLN1. Simultaneous MPA and 8-Br-cAMP treatment synergistically enhanced HAND2 mRNA levels. P and all the progestins significantly increased HAND2 mRNA levels, whereas E(2), 8-Br-cAMP, or dexamethasone alone had no effect. Silencing of HAND2 expression significantly reduced FBLN1 expression, whereas FBLN1 silencing had no effect on HAND2 expression. These results suggest that progestin-induced HAND2 contributes to FBLN1 expression in human ESCs.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
8-Bromoadenosine 3′,5′-cyclic monophosphate sodium salt, ≥97% (HPLC), powder
Sigma-Aldrich
8-Bromoadenosine 3′,5′-cyclic monophosphate, ≥97% (HPLC)